Aldeyra Reports Lower Itching, Discomfort For Reproxalap Vs Xiidra In Dry Eye Patients

Aldeyra Therapeutics, Inc. (ALDX) announced positive data from a Phase 2 clinical trial comparing ocular discomfort and itching symptom scores of reproxalap ophthalmic solution 0.25%, an investigational new drug, versus Xiidra or lifitegrast ophthalmic solution 5 percent in patients with dry eye disease.

The double-masked, crossover, single-center, Phase 2 clinical trial in 56 dry eye disease patients evaluated ocular discomfort and itching and were statistically lower with reproxalap than with Xiidra.

Earlier a trial has demonstrated tolerability advantages of reproxalap over Xiidrain patients with dry eye disease.

The company said the combination of rapid activity and improved tolerability evidenced by reproxalap will help address compliance issues with currently available therapy.

Peter Couroux, Global Senior Medical Director for Cliantha Research and the principal investigator of the clinical trial noted that if approved, reproxalap has the potential to become a first-line therapy for the treatment of dry eye disease.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Ryanair Holdings Plc reported Monday a loss in its fiscal year 2022, narrower than last year, with strong growth in traffic and load factor. Looking ahead, the company said it expects to return to reasonable profitability in fiscal 2023. Shares of the low fares airline were losing around 4 percent in the morning trading in Germany. The U.S. Department of Agriculture's Food Safety and Inspection Service or FSIS has issued a public health alert against Weis Markets' ready-to-eat or RTE General Tso Chicken meals due to misbranding and undeclared milk, a known allergen. The RTE General Tso Chicken meals were prepared, labeled and sold in the Deli area at Weis Markets stores between April 13 and May 11, 2022. Deutsche Telekom AG on Friday raised its fiscal 2022 adjusted earnings forecast after reporting significantly higher net profit in its first quarter. Shares of the German telecom major were gaining around 1 percent in the morning trading in Germany. For fiscal 2022, the company now expects to post adjusted EBITDA AL of more than 36.6 billion euros.
Follow RTT